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REVIEW ARTICLE

Regional distribution of serotonergic receptors:
a systems neuroscience perspective on the
downstream effects of the multimodal-acting
antidepressant vortioxetine on excitatory and
inhibitory neurotransmission
Alan L. Pehrson,1* Theepica Jeyarajah,1 and Connie Sanchez1,2
1
2

External Sourcing and Scientific Excellence, Lundbeck Research USA, Inc., Paramus, New Jersey, USA
Clinical Medicine Department, Aarhus University, Aarhus, Denmark

Previous work from this laboratory hypothesized that the multimodal antidepressant vortioxetine enhances cognitive
function through a complex mechanism, using serotonergic (5-hydroxytryptamine, 5-HT) receptor actions to modulate
gamma-butyric acid (GABA) and glutamate neurotransmission in key brain regions like the prefrontal cortex (PFC) and
hippocampus. However, serotonergic receptors have circumscribed expression patterns, and therefore vortioxetine’s
effects on GABA and glutamate neurotransmission will probably be regionally selective. In this article, we attempt to
develop a conceptual framework in which the effects of 5-HT, selective serotonin reuptake inhibitors (SSRIs), and
vortioxetine on GABA and glutamate neurotransmission can be understood in the PFC and striatum—2 regions with
roles in cognition and substantially different 5-HT receptor expression patterns. Thus, we review the anatomy of the
neuronal microcircuitry in the PFC and striatum, anatomical data on 5-HT receptor expression within these
microcircuits, and electrophysiological evidence on the effects of 5-HT on the behavior of each cell type. This analysis
suggests that 5-HT and SSRIs will have markedly different effects within the PFC, where they will induce mixed effects
on GABA and glutamate neurotransmission, compared to the striatum, where they will enhance GABAergic
interneuron activity and drive down the activity of medium spiny neurons. Vortioxetine is expected to reduce
GABAergic interneuron activity in the PFC and concomitantly increase cortical pyramidal neuron firing. However in
the striatum, vortioxetine is expected to increase activity at GABAergic interneurons and have mixed excitatory and
inhibitory effects in medium spiny neurons. Thus the conceptual framework developed here suggests that vortioxetine
will have regionally selective effects on GABA and glutamate neurotransmission.
Received 9 March 2015; Accepted 3 June 2015
Key words: 5-HT receptor, GABA, glutamate, Lu AA21004, vortioxetine.

’

Clinical Implications
’

Serotonin neurotransmission can modulate the behavior of
GABA and glutamate cells.

’

Serotonin’s effects on GABA and glutamate neurotransmission depend on regional and cellular receptor expression
patterns, as well as the structure of local neuronal circuits.

* Address for correspondence: Dr. Alan L. Pehrson, External Sourcing
and Scientific Excellence, Lundbeck Research USA, Inc., Paramus, NJ
07652, USA. (Email: apeh@lundbeck.com)

5-HT, SSRI antidepressants, and the multimodal antidepressant vortioxetine have markedly different effects on
excitatory and inhibitory neurotransmission in the prefrontal
cortex and striatum.

Introduction
Cognitive dysfunction is a common but poorly understood aspect of major depressive disorder (MDD). MDD
patients commonly experience impairments in a broad
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range of cognitive domains including attention, executive function, working memory, and psychomotor processing speed.1 Although there are a number of relatively
effective treatments for the mood symptoms associated
with MDD, empirical data suggest that many patients
continue to experience high levels of functional disability
despite improvements in depression symptoms.1
Furthermore, neurocognitive impairment predicts
functional outcomes in MDD patients.2 Therefore,
developing treatments capable of normalizing cognitive
function in MDD patients is an important goal for
restoring normal functional ability.
Vortioxetine is an antidepressant that recently has been
approved for treatment of MDD. In 3 double-blind,
randomized, placebo-controlled clinical studies, vortioxetine has shown positive effects on predefined cognition
outcome measures in MDD patients with cognitive
dysfunction, 2 of which included the active reference
duloxetine.3–5 Evidence from a large number of preclinical
studies in rodents also supports a procognitive profile of
vortioxetine and provides a mechanistic hypothesis for its
pharmacological actions. Vortioxetine restored cognitive
function across a range of rodent models of memory and
cognitive flexibility applying cognitive disruptors such as
time, serotonin (5-hydroxytryptamine; 5-HT) depletion,
age, ovariectomy, N-methyl-D-aspartate (NMDA) receptor
antagonism, and muscarinic cholinergic receptor antagonism.6–12 Furthermore, in a quantitative electroencephalographic analysis in rats, vortioxetine dose-dependently
increased cortical oscillatory power, suggesting that
vortioxetine modulates cortical networks recruited during
cognitive behaviors.13
Vortioxetine is thought to exert its pharmacological
effects through a multimodal mechanism of action14 that
involves modulation of 5-HT receptors and inhibition of
the serotonin transporter (SERT). In vitro studies in
cellular assays show that vortioxetine is a 5-HT3, 5-HT7,
and 5-HT1D receptor antagonist; a 5-HT1B receptor
partial agonist; a 5-HT1A receptor agonist; and a 5-HT
reuptake inhibitor.15 However, although the pharmacological effects of this drug are relatively well understood,
the precise mechanism underlying vortioxetine’s
cognitive enhancing properties has yet to be fully
elucidated. Although vortioxetine may indirectly
modulate several neurotransmitter systems, previous
work from this laboratory has advanced the hypothesis
that vortioxetine enhances cognitive function by modulating gamma-aminobutyric acid (GABA) neurotransmission through its direct pharmacological actions on
serotonergic receptors.16 These changes in GABA
neurotransmission induce downstream increases in
glutamate neurotransmission and neuroplasticity in key
brain areas, such as the hippocampus and prefrontal
cortex. In support of this hypothesis, electrophysiology
studies have shown that vortioxetine through 5-HT3

receptor antagonism stimulated glutamatergic pyramidal
neurons in rat hippocampus slices and in the medial
prefrontal cortex of anesthetized rats.17,18 The fact that
5-HT3 receptors in the rat brain are almost exclusively
expressed on GABA interneurons that exert inhibitory
control over pyramidal neurons further supports the
hypothesis.19 Work is currently ongoing to assess to what
extent other portions of vortioxetine’s pharmacological
profile play a role in its effects on GABA and glutamate
neurotransmission.
An interesting corrollary to the idea that vortioxetine
modulates GABA and glutamate neurotransmission
through its pharmacological actions on 5-HT receptors
is the idea that these effects may be regionally specific.
Although serotonergic receptors are broadly expressed
throughout the mammalian brain, the presence of
individual receptor subtypes is regionally circumscribed.
For example, simple visual inspection of autoradiographic maps of vortioxetine’s receptor targets demonstrates that although each of vortioxetine’s major
pharmacological targets is expressed within the medial
prefrontal cortex (mPFC; Figure 1), several of those
receptor targets (notably 5-HT1A and 5-HT3 receptors)
are not present or are present at very low levels within
the striatal caudate and putamen subregions (CPu;
Figure 2). Thus, the likelihood that vortioxetine will
affect striatal neurotransmission in the same manner as it
affects frontal cortex neurotransmission is small.
The goal of this article is to derive specific hypotheses
about how vortioxetine will affect neural activity, with a
particular focus on principle output cells, within the
rodent mPFC and striatum. These brain regions were
chosen because they play a role in aspects of cognitive
function and have markedly different profiles of serotonergic receptor expression. Toward this end, we will
discuss the functional organization of the microcircuits
comprising the prefrontal cortex (PFC) and striatum,
including a discussion of important neuronal
subtypes and their relationships to one another. We will
discuss the regional distribution of serotonergic receptor
targets and the cell types expressing each target
before evaluating the way that 5-HT modulates the
function of the various cellular players within the circuit
in question. Finally we will make predictions on how an
SSRI or the multimodal antidepressant vortioxetine
might modulate the function of the circuit before
evaluating the electrophysiological data on these effects,
where available.

The Prefrontal Cortex
Functional roles and circuit organization
The neocortex is a large structure that serves as an
association region, integrating and performing
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FIGURE 1. Expression pattern of serotonergic targets of the multimodal antidepressant vortioxetine within the rat prefrontal cortex. Autoradiographic images
representing total (left panels) and nonspecific binding (right panels) for each of vortioxetine’s separate serotonergic targets in coronal rat brain sections at
approximately 2.7 mm anterior from Bregma (according to Paxinos and Watson113). 5-HT1A receptors were mapped using 3nM [3H]8OHDPAT alone (A) or in
combination with 1 µM of the 5-HT1A receptor selective antagonist WAY100635 to determine nonspecific binding (B). 5-HT1B/1D receptors were mapped using
1nM [3H] GR125743 alone (C) or in combination with 1 µM of the 5-HT1B receptor preferring antagonist SB216641 to determine nonspecific binding (D). 5-HT3
receptors were mapped using 3nM [3H] LY278584 alone (E) or in combination with 1 µM ondansetron to determine nonspecific binding (F). 5-HT7 receptors were
mapped using 4.5nM [3H]SB269970 alone (G) or in combination with 1 µM of unlabeled SB269970 to determine nonspecific binding (H). Finally, SERT was
mapped using 4.5 nM [3H] escitalopram alone (I) or in combination with 1 µM paroxetine to determine nonspecific binding (J). Scale bars represent 5 mm.
Abbreviations: mPFC – medial prefrontal cortex.

4 A. L. PEHRSON ET AL.

FIGURE 2. Expression pattern of serotonergic targets of the multimodal antidepressant vortioxetine within the rat striatum. Autoradiographic images
representing total (left panels) and nonspecific binding (right panels) for each of vortioxetine’s separate serotonergic targets in coronal rat brain sections at
approximately 1.6 mm anterior from Bregma (according to Paxinos and Watson113). 5-HT1A receptors were mapped using 3nM [3H]8OHDPAT alone (A) or in
combination with 1 µM of the 5-HT1A receptor selective antagonist WAY100635 to determine nonspecific binding (B). 5-HT1B/1D receptors were mapped using
1nM [3H] GR125743 alone (C) or in combination with 1 µM of the 5-HT1B receptor preferring antagonist SB216641 to determine nonspecific binding (D). 5-HT3
receptors were mapped using 3nM [3H] LY278584 alone (E) or in combination with 1 µM ondansetron to determine nonspecific binding (F). 5-HT7 receptors were
mapped using 4.5nM [3H]SB269970 alone (G) or in combination with 1 µM of unlabeled SB269970 to determine nonspecific binding (H). Finally, SERT was
mapped using 4.5 nM [3H] escitalopram alone (I) or in combination with 1 µM paroxetine to determine nonspecific binding (J). Scale bars represent 5 mm.
Abbreviations: CPu – caudate/putamen.
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FIGURE 3. Serotonergic influence on a theoretical prefrontal cortex microcircuit. The influence of serotonin on the behavior of cortical pyramidal
neurons is mediated by several different factors. Non-parvalbumin-immunoreactive interneurons (depicted in red) in the shallow cortical layers receive
serotonergic inputs that have mixed excitatory and inhibitory effects mediated via 5-HT1A, 5-HT2A, and 5-HT3 receptors (A) and have an inhibitory
influence on pyramidal cell dendritic membrane polarization. Additionally, serotonin’s effects on parvalbumin-immunoreactive interneurons
(depicted in purple) are also probably a mix of excitatory and inhibitory actions that are mediated by 5-HT1A, 5-HT2A, and perhaps 5-HT1B receptors (B).
These cells exert a powerful inhibitory effect on pyramidal neuron activity via hyperpolarizing actions at the pyramidal neuron soma or axon hillock. Pyramidal
neurons themselves (depicted in blue) also receive a mix of excitatory and inhibitory serotonergic signals, which are mediated by 5-HT1A, 5-HT2A/2C, 5-HT4,
5-HT5, 5-HT6, and 5-HT7 receptors (C). Finally, glutamate release from pyramidal neuron terminals in the prefrontal cortex may be inhibited by 5-HT1B receptor
activation (D).

computations on information from numerous other brain
regions. The PFC represents a specialized subset of the
neocortex that mediates a variety of cognitive functions,
including learning,20 working memory,21 attention,22 and
behavioral flexibility.23
The PFC is a complex structure where neurons
are incorporated into a modular design featuring
columns of neurons as a basic unit of information
processing. Each column is organized into well-defined
layers that feature distinct populations of cells or cellular
features, which are depicted in Figure 3. As discussed in
a recent review by Puig and Gulledege,24 layer I is
primarily a neuropil layer, featuring afferent terminals
from a variety of sources and the cell bodies of regular
spiking GABAergic interneurons and glia. Layers II
and III contain the cell bodies of small pyramidal
neurons and GABAergic interneurons characterized by
either regular- or fast-spiking behavior. Layers V and VI
contain the cell bodies of large pyramidal neurons as well
as GABAergic interneurons primarily characterized by
fast-spiking behavior. While an in-depth discussion of
each cell type is outside the scope of this review, we will
briefly discuss the role of these different cell types and
their relationships to one another in the following
section.

Important cortical cell types
Parvalbumin-immunoreactive (PV-IR) fast-spiking interneurons

One major category of cortical inhibitory interneuron
can be identified by the expression of the calcium
binding protein parvalbumin (PV). There are several
subclasses of cortical inhibitory interneuron that express
PV, which at least include a subset of basket cells and
chandelier cells (for an excellent review, see Kubota25).
PV-IR interneurons primarily have fast-spiking behavior,
and thus for the purposes of this article, the terms “PVIR interneuron” and “fast-spiking interneuron” will be
used interchangeably. Importantly, each PV-IR interneuron subtype is thought to have a selective subcellular
axonal target. PV-IR basket cells, which comprise
approximately 40–50% of cortical non-pyramidal neurons, arborize at the soma and dendrites of pyramidal
neurons, with each basket cell innervating between 200
and 1000 pyramidal cells.25 PV-IR chandelier cells are a
relatively small subset of PV-IR interneurons and synapse
with pyramidal neurons almost exclusively at the axon
hillock.25 Given the placement of these axonal arborizations, cortical PV-IR interneurons can be expected to
have a strong inhibitory effect on the output of pyramidal
neurons. Interestingly, PV-IR interneuron subclasses
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such as fast-spiking basket cells are thought to be
connected to one another via electrical gap junctions,25
which may allow these cell types to easily form neural
assemblies that could multiply the inhibitory signal they
represent within the frontal cortex network.
Non-PV-IR interneurons

In addition to PV-IR interneurons, there are a number of
other GABAergic interneuron classes in the frontal
cortex. These subtypes can be identified by various
neurochemical markers, including calbindin, calretinin,
cholecystokinin, vasoactive intestinal peptide, somatostatin, and neuropeptide Y. Each interneuron subtype has
a distinctive morphology, cellular target, and role in
modulating the activity of frontal cortical networks.25
Furthermore, the electrical activity of these cells
can have a regular-spiking, late-spiking, or bursting
character. However, information on the placement of
serotonergic targets on these cortical interneuron subtypes has generally not reached a high level of detail.
Therefore, we have chosen to consider these various
classes together as one group for the purposes of this
article. The most important group of non-PV-IR
interneurons to consider from the perspective of understanding serotonergic neurotransmission’s effects on
PFC activity is a set of interneurons in the shallow
cortical layers (ie, layers I–III) that inhibits cortical
pyramidal neuron activity.
Pyramidal neurons

Pyramidal neurons are excitatory glutamatergic cells that
are characterized by a triangular-shaped soma, apical
dendrites emanating from the soma’s vertex, and basal
dendrites as well as a single branching axon originating
from the soma’s base. Within the cortex, pyramidal
neurons are thought to fill multiple functional roles. The
small pyramidal neurons prevalent in layers II and III
integrate subcortical and cortico-cortical afferent inputs
and send axonal projections horizontally to layers II
and III of neighboring cortical columns.26,27
Additionally, layer II/III pyramidal neurons project
axons vertically to layer V pyramidal neurons.26,27 This
combination of local projections drives lateral inhibitory
effects on layer II/III pyramidal neurons from neighboring cortical columns, presumably by activating inhibitory
interneurons, while also activating layer V pyramidal
neurons both within the originating column and in
neighboring columns.26 Thus, activation of a given layer
II/III pyramidal neuron may suppress inputs from
neighboring columns while at the same time magnifying
the output of its own column.
The pyramidal neurons of the deep cortical layers
(ie, layers V and VI) have a large soma in comparison to
layer II/III pyramidal neurons, and layer V pyramidal

neurons are responsible for sending excitatory glutamatergic projections to subcortical regions, such as the
striatum. Thus, the pyramidal neuron is considered the
principle cortical projection neuron.
In order to understand how 5-HT modulates PFC
microcircuit activity, it is necessary to understand which
cells within the network express each receptor and their
effect on neural activity. Therefore, the following section
will review information on 5-HT receptor expression
within the PFC.

Serotonergic receptor expression in the prefrontal cortex
5-HT1A receptors

5-HT1A receptors are inhibitory G-protein coupled
receptors. Autoradiographic and immunohistochemical
studies have demonstrated strong 5-HT1A receptor
expression in some portions of the hippocampal formation (see the detailed review by Dale et al 28 elsewhere in
this issue) and the brain stem raphe nuclei. 5-HT1A
receptor expression within the PFC is moderate in
strength (Figure 1, panels A and B), and has been
demonstrated in all cortical layers with the exception of
layer I.29
Aznar et al29 investigated the cellular subtypes that
express the 5-HT1A receptor in the rodent cortex, and
found that the majority of pyramidal neurons, PV-IR
interneurons, and some non-PV-IR interneurons express
5-HT1A receptors (approximately 85% or more in each
case). However, it should be noted that other research
groups have suggested lower estimates in PFC subregions, with approximately 60% of pyramidal neurons
in the prelimbic, and 40% of those in the infralimbic
subregion, expressing 5-HT1A receptor messenger ribonucleic acid (mRNA).30 Approximately 20% of GABAergic interneurons in these PFC subregions express
5-HT1A receptors.30
On a subcellular level, 5-HT1A receptors are thought
to be somatodendritically expressed, and in frontal
cortex pyramidal neurons there is evidence supporting
a placement on the axon hillock.31
Based on this pattern of expression, 5-HT1A receptors
can be expected to have complex effects on the behavior
of the frontal cortex. Activation of 5-HT1A receptors
expressed on PV-IR interneurons would inhibit these
cells, and thereby allow pyramidal neuron firing to
increase via disinhibition. However, 5-HT1A receptor
expression on pyramidal neurons themselves would
reduce their activation state. Therefore, 5-HT1A receptor
activation should have mixed effects on the behavior of
the PFC microcircuit. Moreover, electrophysiological
evidence suggesting that selective activation of 5-HT1A
receptors leads to an increase in firing followed by a
reduction for most pyramidal neurons32 is consistent
with this conceptual framework.
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5-HT1B receptors

Within the frontal cortex, 5-HT1B receptors are
expressed at low to moderate levels33–35 (Figure 1, panels
C and D) and may exist with a combination of presynaptic
and postsynaptic expression patterns. The observation
that 5-HT1B receptor stimulation reduces extracellular
5-HT concentrations elicited by SSRIs in the frontal
cortex suggests the presence of 5-HT1B receptors on
serotonergic terminals in this region.36 Additionally,
Tanaka and North37 have suggested that 5-HT1B receptors are present as postsynaptic terminal heteroreceptors
on cortical glutamate terminals, as 5-HT1B receptors
modulate cortical glutamate release. However, this
should be viewed with caution, since there is no
histological confirmation. Egeland et al38 demonstrated
5-HT1B receptor immunoreactivity within a subpopulation of PV-IR interneurons of the cingulate gyrus, and
this included some weak immunoreactivity in the soma of
these cells. It is not known whether this expression
pattern reflects somatodendritic insertion of 5-HT1B
receptors on the neuronal membrane, as has been
observed in the hippocampal formation,39,40 or simply
5-HT1B receptors that are early in the process of being
trafficked to axon terminals.
Thus, activation of 5-HT1B receptors may negatively
modulate the release of 5-HT and glutamate within the
frontal cortex via their expression as terminal autoreceptors or heteroreceptors. Additionally, if 5-HT1B receptors
have a somatodendritic expression in cortical PV-IR
interneurons, then activation of these receptors may also
serve to reduce the activity of these neurons. However, we
have not been able to identify any electrophysiological
studies confirming the presence of a 5-HT1B mediated
current in cortical PV-IR interneurons.
Given that Bruinvels et al33 found that the closely
related 5-HT1D receptor represents a negligible amount
of binding in the frontal cortex, we will consider it to be
absent in the PFC and will discuss it in more detail below,
in the section dealing with the striatum.
5-HT2A/2C receptors

5-HT2 receptors are stimulatory G-protein coupled
receptors that exist primarily as postsynaptic heteroreceptors within the CNS. 5-HT2A receptors are strongly
expressed in the cortex. Within the frontal cortex,
5-HT2A receptor mRNA has been observed in pyramidal
neurons and interneurons, with substantial variation in
the proportion of these cellular populations expressing
this receptor. In the prelimbic PFC, approximately
one-half of pyramidal neurons and one-third of interneurons express 5-HT2A receptor mRNA, while in the
infralimbic region only about 12% of pyramidal neurons
and 22% of interneurons expressed 5-HT2A receptors.30
Moreover, the presence of 5-HT2A receptor proteins has
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been confirmed in each of these cell populations.41
Furthermore, the presence of 5-HT2A receptors on
GABAergic interneurons has been extended, showing
these receptors are present in cortical PV-IR and non-PVIR interneurons.42,43
The structurally similar 5-HT2C receptor is present at
moderate levels in the frontal cortex,44 but has not been
found in fast spiking interneurons.42
Thus, within the frontal cortex, activation of 5-HT2A
and 5-HT2C receptors is expected to have excitatory
direct effects on pyramidal neurons, while 5-HT2A
receptors should also excite GABAergic interneurons.
However, given the tight interconnection between
pyramidal and GABAergic interneurons in the frontal
cortical microcircuitry, the effects of 5-HT2A/2C receptor
stimulation are expected to be mixed. Moreover, the
available electrophysiological evidence is consistent with
this interpretation. In vivo recordings of the PFC after
administration of the 5-HT2A/2C receptor agonist 2,5dimethoxy-4-iodoamphetamine (DOI) found that regular
spiking cells had a mix of excitatory and inhibitory
responses,45 although the largest group of DOIresponsive neurons exhibited an excitatory response.

5-HT3 receptors

5-HT3 receptors are unique among the known 5-HT
receptor subtypes in that they are the only stimulatory
ligand-gated ion channel. On a regional level, 5-HT3
receptors are expressed at their strongest levels within
the CNS in the nucleus of the solitary tract, and their
level of expression in forebrain regions tends to be low to
moderate by comparison.46 Within the frontal cortex,
cells expressing 5-HT3 receptor mRNA are segregated
primarily into shallow cortical layers (ie, layers I–III),
although some 5-HT3 receptor mRNA-positive cells have
been observed in deeper layers.47 5-HT3 receptor protein
expression in the frontal cortex tends to be present
throughout the cortical layers, though again it is stronger
in the shallow layers46,48 (see Figure 1, panels E and F).
On the level of cellular expression, 5-HT3 receptors are
nearly exclusively expressed within GABAergic interneurons, more specifically in those expressing cholecystokinin, calretinin, vasoactive intestinal peptide, or
neuropeptide Y, but not in those expressing somatostatin
or parvalbumin.24,49
Thus, 5-HT3 receptors represent a mechanism of
5-HT-mediated fast excitatory drive that is selective to
non-PV-IR interneurons segregated into layers I–III. By
extension, it can be expected that 5-HT3 receptormediated 5-HT neurotransmission will have an overall
inhibitory effect on the output of cortical pyramidal cells,
especially in the PFC, where there are somewhat more
5-HT3 receptors than in other cortical subregions.
Electrophysiological data are consistent with this
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interpretation. Puig et al47 demonstrated that raphe
stimulation increased the activity of a subset of GABAergic interneuron that could be blocked by selective 5-HT3
receptor antagonists, while Ashby et al50 found that
5-HT3 receptor agonists reduced the activity of putative
pyramidal neurons in the PFC. By extension, 5-HT3
receptor antagonists can be expected to increase
pyramidal neuron output via disinhibition.
5-HT4 receptors

5-HT4 receptors are stimulatory G-protein coupled
receptors for which there is relatively little accumulated
knowledge. Autoradiographic evidence suggests that
5-HT4 receptors are expressed at very low levels in the
frontal cortex.51 Furthermore, there is little and
conflicting experimental data addressing their cellular
expression in the frontal cortex.38,52
5-HT5 receptors

5-HT5 receptors are inhibitory G-protein coupled receptors that are broadly present within the rodent brain.
Immunohistochemical evidence shows low to moderate
5-HT5 receptor expression levels within several cortical
regions, highest within layers II and IV, where expression
tended to be in the soma,53 but the degree to which this
information will translate to the PFC is questionable,
since this region lacks a well-defined layer IV. Anatomical data on the cortical neuronal subtypes expressing
5-HT5 receptors is largely absent; however, Goodfellow
et al54 observed a 5-HT5 receptor-mediated inhibitory
current in cortical layer V pyramidal neurons, suggesting
that they are at least present in cortical principle cells.
Based on these data alone, activating 5-HT5 receptors
should be expected to reduce cortical output. However,
given the relative lack of anatomical and electrophysiological data on this receptor subtype, 5-HT5 receptors
may turn out to have more complex actions on the PFC
network.
5-HT6 receptors

5-HT6 receptors are stimulatory G-protein coupled
receptors that are present at low to moderate levels
within the rodent frontal cortex, with stronger areas of
expression in rostral compared to caudal cortical
regions.55 Similar results were found in human PFC,
where 5-HT6 receptor expression was present at
relatively low levels.56 The strongest 5-HT6 receptor
expression in the human cortex was observed in layer I,
where 5-HT6 receptors were primarily associated with
glia. However, 5-HT6 receptor expression was associated
with pyramidal neurons in deeper cortical layers,56 and
expression in non-pyramidal neuronal types has not yet
been reported. These data may suggest that 5-HT6
receptor activation will activate pyramidal neuron firing;

however, we are not aware of any electrophysiology data
that have investigated the consequences of 5-HT6
receptor stimulation in the PFC.
5-HT7 receptors

5-HT7 receptors are stimulatory G-protein coupled
receptors that have varying levels of expression within
the cortex, with strong expression in the shallow cortical
layers and more moderate levels in deeper layers57
(Figure 1, panels G and H). More specifically, 5-HT7
receptor expression has been observed in layer V
pyramidal neurons, and in cells with relatively small
oval-shaped soma that were not characterized further.
Electrophysiological evidence indicates the presence of
5-HT7 receptors on hippocampal pyramidal neurons58
and GABAergic interneurons59; thus it is possible that
they will also be present in cortical interneurons, but this
remains to be experimentally confirmed. A study by
Tokarski et al60 showed that acute intraperitoneal (i.p.)
administration of the selective 5-HT7 receptor antagonist SB269970 at 1.25 mg/kg had no effect on the firing
of frontal cortex pyramidal neurons, while repeated
administration reduced firing. But Lundbeck internal
data suggest that a 1 mg/kg dose of this drug via the
subcutaneous (s.c.) route, which is in many respects
similar to the i.p. route, results in negligible occupancy
at 5-HT7 receptors. In fact, in our hands, a 30 mg/kg
dose of SB269970 only engendered approximately 30%
of 5-HT7 receptors 1 hour after administration, owing to
difficulty penetrating the blood–brain barrier. Given
these receptor occupancy data, it remains unclear how
5-HT7 receptor modulation will alter the activity of cells
within the PFC.

Summary of serotonergic receptor mechanisms in frontal
cortex neuronal subtypes
This section summarizes the 5-HT receptor subtypes that
have been demonstrated on each of the important
neuron types within the PFC microcircuit.
PV-IR interneurons

In cortical PV-IR fast-spiking interneurons, there is
evidence supporting the expression of inhibitory 5-HT1A
as well as excitatory 5-HT2A receptors, although 5-HT1A
and 5-HT2A receptors appear to be largely expressed by
separate populations of PV-IR interneurons.42 There is
also some evidence suggesting that 5-HT1B receptors are
expressed on cortical PV-IR interneurons, but the
subcellular localization of 5-HT1B receptors on cortical
PV-IR cells is not clear at this time. Based on this
evidence, cortical PV-IR cells will likely respond to 5-HT
with either an excitatory or inhibitory response on the
single-cell level, while on the population scale there will
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TABLE 1. 5-HT receptor subtypes in the rat prefrontal cortex and striatum: expression patterns, affinities for 5-HT, and effects on neural activity.
Expression
Receptor

Direct effect on neural activation

Affinity for 5-HT Ki or KD (nM)

5-HT1A

I

0.2–0.79

5-HT1B

I

5-HT1D
5-HT2A

PFC

Cell Ttypes

Striatum

PFC

Striatum

Ref.

++

+/−

–

28,29,92

4.0–32

++

++/+++

2.5–6.3
1.3

−
+++

+
++

PV-IR IN
ChAT-IR IN
?
MSN

32–34,37

I
S

5-HT2C

S

2.5–160

++

++

Pyr
PV-IR IN
Non-PV-IR IN
Pyr
IN (PV-IR)
?
Pyr
PV-IR IN
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likely be a mixed excitatory and inhibitory response.
Whether this population level mix of excitatory and
inhibitory responses skews to one side or the other may
depend on a number of issues, including (1) how
commonly 5-HT1A and 5-HT2A receptors are expressed
within frontal cortical PV-IR cells, (2) the affinity of
5-HT for each of these targets (Table 1), and (3) the
concentration of 5-HT applied to the neural system.
Puig et al42 have suggested that about half of PV-IR
interneurons in layers II/III express 5-HT1A receptor
mRNA, while about 20% express 5-HT2A receptor mRNA.
However, in layer V, approximately one-third of PV-IR
neurons express 5-HT1A receptors, while a separate third
of the population express 5-HT2A receptors. Thus, these
data may suggest that PV-IR interneurons in shallow
cortical layers are more likely to be inhibited by 5-HT than
those in deep cortical layers, where there is more
likelihood for an even split in excitatory and inhibitory
responses within this cell population. However, given that
5-HT’s affinity for the 5-HT1A receptor is anywhere from
1.6- to 6.5-fold higher than for the 5-HT2A receptor
(Table 1), it is possible that the effect of 5-HT on cortical
fast-spiking interneuron behavior will skew more heavily
toward inhibition at lower levels of 5-HT concentrations,
with excitation becoming more prominent as 5-HT
concentrations increase.

Non PV-IR interneurons

In non-PV-IR cortical GABAergic interneurons, there is
evidence to support 5-HT1A receptor expression on

calbindin-IR interneurons, and 5-HT3 receptors have
been found on CR-IR and CCK-IR interneurons located
in shallow cortical layers. Additionally, electrophysiological evidence has suggested that 5-HT2A receptors are
also present in cortical non-PV-IR interneurons,
although the specific subtype remains unclear at this
time. When considering the overall effects of 5-HT in
this subpopulation of cells, inhibitory 5-HT1A receptors
may again tend to predominate in low concentration
ranges of 5-HT, given its higher affinity for the
endogenous ligand by comparison to 5-HT2A and
especially 5-HT3 receptors (Table 1). However, it is
important to note that it is essentially unknown at this
time whether these receptors are expressed in serotonergic synapses. Although SERT expression in the
frontal cortex is relatively strong (see Figure 1, panels I
and J), it is currently believed that only about one-quarter
of serotonergic terminals in this brain region have
synaptic specializations.61 However, the serotonergic
terminals that do form synapses are thought to be
primarily on GABAergic interneurons residing in the
shallow cortical layers,62 which may include 5-HT3
receptor-expressing interneurons. If true, this pattern
may make it easier to achieve sufficiently high 5-HT
concentrations to stimulate 5-HT3 receptor activity than
for those serotonergic receptor targets that are primarily
modulated by extracellular serotonin concentrations.
Additionally, 5-HT3 receptors are a fast-desensitizing
serotonergic target (for example, see Dale et al17); thus at
high concentrations, it may be the case that a larger
proportion of this receptor population is non-functional
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than at lower concentrations. Taken together, it is
reasonable to suggest that serotonergic neurotransmission is more likely to activate non-PV-IR interneurons in the shallow cortical regions.
Pyramidal neurons

In cortical pyramidal neurons, there is evidence for the
expression of a variety of serotonergic receptors.
Inhibitory 5-HT1A and 5-HT5 receptors have been found
in somatodendritic subcellular regions of pyramidal
neurons, 5-HT1B receptors may be expressed in the
terminals of cortical pyramidal neurons. Additionally,
several excitatory serotonergic receptors are present on
these cells, including 5-HT2A, 5-HT2C, 5-HT4, 5-HT6,
and 5-HT7 receptors.
Given the wide range of excitatory and inhibitory
serotonergic receptors that have been demonstrated in
cortical pyramidal neurons, along with the differences in
affinity these receptors have for 5-HT, it is not possible to
accurately determine 5-HT’s overall effects on cortical
pyramidal neurons. However, within the native frontal
cortex microcircuit, pyramidal neurons are under powerful inhibitory control from a variety of inhibitory
interneurons, and thus some of the effects 5-HT will
have on pyramidal neurons will depend on its effects on
these inhibitory interneurons.

Electrophysiological effects of 5-HT in the frontal cortex
In vivo electrophysiology

Studies that have investigated the effects of 5-HT on
cortical fast-spiking (presumably PV-IR) interneuron
behavior in vivo using anesthetized animals have
generally found that 5-HT has inhibitory effects. For
example, Puig et al42 found that stimulating the midbrain
raphe nuclei at low levels and recording in vivo from the
medial PFC induced mixed effects in fast-spiking
interneurons, with the majority of these cells exhibiting
inhibition (61%), and small populations exhibiting
excitation (approximately 10%) or excitation followed
by inhibition (approximately 6%). Moreover, the inhibitory actions of raphe nucleus stimulation were antagonized by administration of the selective 5-HT1A
receptor antagonist WAY100635, whereas the few
excitations that were observed were antagonized by the
5-HT2 receptor antagonist ritanserin.
Superficially, these data appear to be at odds with data
from the same lab demonstrating that separate but equal
proportions of layer V PV-IR interneurons within the
cortex express inhibitory 5-HT1A receptors and excitatory 5-HT2A receptors42. A corollary to these data would
seem to be that approximately equal proportions of layer
V fast-spiking interneurons would exhibit an inhibitory
or excitatory response to physiological 5-HT levels.
However, during periods of light anesthesia that more

closely resembled an “awake” cortical network, Puig
et al.42 also found a higher proportion of cells exhibiting
an excitatory response to raphe stimulation (approximately 31% compared to 10%). These data fit with an
interpretation that in vivo electrophysiology in anesthetized rats is biased towards 5-HT1A receptor mediated
inhibition.
Although inhibition of PV-IR interneurons would be
expected to have a disinhibitory effect on pyramidal
neurons, it seems that pyramidal neurons also have an
overwhelmingly inhibitory response to raphe nucleus
stimulation in anesthetized in vivo electrophysiological
experiments. Puig et al63 demonstrated that low-level
stimulation of the raphe nucleus inhibited activity in the
majority of recorded putative pyramidal neurons (66%),
while 13% exhibited an excitatory response and another
20% had mixed effects characterized by inhibition
followed by excitation. 5-HT1A receptor antagonism
attenuated the inhibitory responses (but did not entirely
block them), while 5-HT2A receptor antagonism blocked
the excitatory responses. Similar results were found by
several other research groups after raphe nucleus
stimulation in anesthetized in vivo electrophysiological
preparations.64–66
While the results of these in vivo anesthetized
electrophysiology experiments consistently suggest that
5-HT has an overwhelmingly inhibitory effect on not only
pyramidal neurons but also PV-IR interneurons, there
are some important limitations to consider when
evaluating these data. The presence of anesthesia may
cause a number of deviations from normal cortical
network states, for example a reduction in tonic or
phasic 5-HT concentrations resulting from reduced
raphe nucleus activity. This may bias the effects of
5-HT stimulation toward receptors with high affinity for
5-HT, such as the inhibitory 5-HT1A receptor, which is
present on pyramidal neurons, as well as multiple
subtypes of non-pyramidal neurons in this region.
It may be the case that in an awake and behaving animal,
stimulation of the raphe nucleus would be more likely to
induce excitatory responses mediated by lower-affinity
receptors, such as the 5-HT2A receptor (Table 1).
In addition to this distal effect of anesthesia, local
cortical networks may also be abnormally regulated by
these unusually high GABAA receptor mediated currents.
This may have the effect of partially divorcing the activity
of pyramidal neurons and some types of interneurons
from the activity of the inhibitory cells governing their
behavior, therefore abrogating the downstream effects of
serotonergic modulation. This, along with the apparent
bias toward 5-HT1A receptor mechanisms, may help to
explain why pyramidal neuron firing is overwhelmingly
reduced by raphe stimulation or SSRI treatments within
anesthetized cortical networks in the face of reduced
fast-spiking interneuron firing.
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In vitro electrophysiology

In stark contrast to the in vivo electrophysiological
techniques in anesthetized rodents, research groups
investigating the effects of 5-HT on fast-spiking interneuron behavior in brain slices have generally found that
5-HT has an activating effect on fast-spiking interneurons. For example, Zhong and Yan67 found that
5-HT (20-40 µM) led to an increased firing rate of fast
spiking interneurons, with relatively little effect of 5-HT
at lower concentrations (1–2 µM). The idea that 5-HT
activates fast-spiking interneuron behavior in slices is
further supported by observations that 5-HT depolarized
fast-spiking interneurons43 and increased spontaneous
inhibitory postsynaptic currents (sIPSCs) recorded from
pyramidal neurons.43,68,69
Additionally, in the concentration ranges that drove
increases in fast-spiking interneuron activity, Zhong and
Yan67 observed concomitant reductions in the firing rate
of cortical pyramidal neurons. But the inhibitory effects
of 5-HT on pyramidal neuron firing were not limited
to downstream actions on GABAergic interneurons.
Araneda and Andrade70 found that 5-HT hyperpolarized
layer V cortical pyramidal neuronal membranes, which
could be blocked by 5-HT1A receptor antagonists but not
a 5-HT2 receptor antagonist.
As expected by the fact that both inhibitory 5-HT1A
and stimulatory 5-HT2A receptors are expressed in
cortical pyramidal neurons, 5-HT’s effects on pyramidal
neuron firing in slice electrophysiological preparations
are not universally inhibitory. Several groups have found
that 5-HT application increases spontaneous excitatory
postsynaptic currents69,71 (sEPSCs), induces membrane
depolarizations,70 and modulates after hyperpolarization currents in a manner that supports increased
activity.70,72
Taken together, in contrast to in vivo recordings in
anesthetized animals, these data from brain slices
suggest that 5-HT has a primarily excitatory effect on
cortical fast-spiking interneurons, as well as mixed
excitatory and inhibitory effects on pyramidal neuron
activation. Slice electrophysiology has a number of
advantages, including a stronger ability to identify the
cell type from which each recording is taken and the
absence of anesthesia. However, there are also limitations to consider. First, although it can be argued that
local neuronal circuits are largely intact, the process of
sectioning tissue does attenuate some aspects of the
neural network, most obviously from distal regions such
as the raphe nucleus. Additionally, it should be noted
that slice electrophysiological studies are often conducted in brain slices collected from adolescent rodents,
and thus the degree to which the results translate to the
adult cortical network are difficult to know. But perhaps
the most important limitation of slice electrophysiology
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in the context of this article is that it is difficult to
ascertain what the effects of physiological 5-HT concentrations would be. It is more or less not possible to
determine whether the 5-HT concentrations used to
elicit a primarily excitatory response via bath application
are physiologically relevant, and in fact the concentrations commonly used to elicit these responses are in a
very high range. Although it is common for slice
electrophysiologists to use relatively high concentrations
of a given ligand to ensure that it penetrates to the
recorded cells (typically in the range of 100–1000 times
Ki), concentrations of 5-HT of 20–40 µM seem disproportionately high from the perspective that the Ki for
5-HT at 5-HT2A receptors is1.3 nM (Table 1).
Thus, it seems likely that in vivo investigations of 5HT’s effects in anesthetized PFC networks primarily
represent the actions of this neurotransmitter at low
concentrations, while those from the slice represent
5-HT’s actions at high concentrations. In order to
further advance our understanding of how 5-HT
and serotonergic antidepressants modulate prefrontal
cortical networks, it would be advantageous to conduct
investigations in awake and behaving rodents.

Hypothesized effects of 5-HT, SSRIs, and vortioxetine on the
overall frontal cortex circuit
5-HT and SSRIs

Based on the receptor profiles that are present in each of
the major cell types we have considered in the frontal
cortex microcircuitry, as well as electrophysiological
evidence of 5-HT’s effects, the emerging theme seems to
be that 5-HT has largely inhibitory actions at low
concentrations dominated by 5-HT1A receptor mediated
actions at some PV-IR and non-PV-IR interneurons.
Under normal circumstances, this would be expected to
disinhibit pyramidal neuron activity, although pyramidal
neurons themselves would also experience direct inhibitory effects of 5-HT1A receptor activation. At higher
levels of 5-HT tone, excitatory actions would start
coming into play at inhibitory interneurons, primarily
mediated by 5-HT2A receptors at PV-IR fast-spiking
interneurons and by 5-HT2A and 5-HT3 receptors in
non-PV-IR interneurons. These actions on cortical
interneurons would be expected to drive a GABAmediated inhibitory influence on pyramidal neuron
firing, particularly given the powerful inhibitory action
PV-IR interneurons have on pyramidal neuron behavior.
However, pyramidal neurons would also experience
some direct excitatory actions of 5-HT mediated through
a variety of serotonergic receptor targets. Therefore, at
multiple levels of organization, 5-HT has opposite
directed effects that overall do not appear to clearly
influence the output of frontal cortical output cells
toward excitation or inhibition. On a conceptual level,
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5-HT may therefore play a role in fine-tuning the output
of frontal cortical networks, acting in a sense as a buffer
that will tend to normalize the activity of pyramidal
output neurons. Given this concept and the idea that
SSRI antidepressants increase synaptic and extrasynaptic
serotonin concentrations without directly modulating
serotonergic receptors, we hypothesize that, under acute
conditions, these treatments will have mixed effects that
will not clearly bias frontal cortex output in either
direction. Moreover, this idea is supported by electrophysiological studies that have demonstrated that acute
and short-term repeated SSRI administration have little
effect on PFC firing in anesthetized rats.73,74 However,
long-term SSRI administration seems to have an inhibitory effect on PFC firing,73,74 which may imply that
desensitization of some serotonergic receptor systems
are important for the long-term effects of SSRI administration on frontal cortical network behavior. It is not
clear based on available anatomical and electrophysiological data precisely which serotonergic receptor
mechanisms might be involved in these effects of chronic
administration.

Vortioxetine

In contrast, vortioxetine should have markedly different
effects on the output of frontal cortex networks that will be
driven by its direct pharmacological actions on several
serotonergic receptors. Vortioxetine’s potent antagonism
of 5-HT3 receptors should remove a source of 5-HTmediated fast excitatory drive on a selective population of
non-PV-IR cortical interneurons localized in shallow
cortical layers. Based on the model presented here, this
action should disinhibit cortical pyramidal neurons,
although it is unclear whether this effect would be
segregated purely in layer II/III pyramidal neurons or if
it would generalize to layer V pyramidal output cells.
5-HT3 receptor antagonism can also result in increased
extracellular 5-HT concentrations when dosed along
with an SSRI,75 which may lead to more stimulation of
serotonergic receptors that are not directly targeted by
vortioxetine. Additionally, 5-HT1A receptor agonism
should induce a fast inhibitory effect mediated by inwardly
rectifying potassium channels in both PV-IR and non-PVIR interneurons, which may also disinhibit pyramidal
neuron activity that would be balanced by inhibitory
actions on the pyramidal neurons themselves. Additionally, vortioxetine’s partial agonist action at 5-HT1B
receptors, which acts to attenuate 5-HT1B receptor actions
in vivo,76 may increase serotonergic tone in the PFC by
reducing inhibitory feedback at the site of the serotonergic
terminal, which may again lead to greater stimulation of
serotonergic targets not directly targeted by vortioxetine.
Furthermore, this partial agonist effect at 5-HT1B receptors may also attenuate 5-HT1B receptor mediated

inhibition of cortical glutamatergic terminals, leading to
increased glutamate release from layer II/III pyramidal
neurons at their local cellular targets. Finally, it is unclear
at this time what effect vortioxetine’s 5-HT7 receptor
antagonist properties will have on PFC activity. But we
expect that the net effect of vortioxetine in the PFC will
be to reduce aspects of GABAergic neurotransmission
and indirectly increase the activity of glutamatergic
pyramidal cells.
In support of these ideas, recent in vivo electrophysiology experiments by Riga et al18 in anesthetized rats
demonstrated that acute administration of the SSRI
escitalopram had no effect on the overall firing rate of
putative frontal cortex pyramidal neurons, although a
relatively equal minority of cells exhibited excitatory or
inhibitory responses. However, in stark contrast, acute
i.v. administration of vortioxetine led to an overwhelmingly excitatory response in cortical pyramidal neurons. This research group also found that an acute
combination of escitalopram and the selective 5-HT3
receptor antagonist ondansetron led to significant
increases in pyramidal neuron firing, at least implicating
a combination of 5-HT reuptake inhibition and 5-HT3
receptor antagonism in vortioxetine’s excitatory effects.
In summary, SSRIs appear to have mixed effects on
the function of the PFC circuit that do not clearly
modulate activity either toward excitation or inhibition
under acute conditions, while acute vortioxetine leads to
an increase in PFC pyramidal neuron activity that is
driven by a reduction in GABAergic inhibitory processes.
After long-term administration, SSRI antidepressants
lead to an overall reduction of PFC pyramidal neuron
firing that is likely driven by the desensitization of some
serotonergic receptors. At this time, empirical data on
the long-term effects of vortioxetine on PFC pyramidal
neuron activity are not available; however, we hypothesize that vortioxetine will still have an overall excitatory
effect on these cells after chronic administration.

The Striatum
Functional role and organization
The striatum, which is a term we will use to refer
specifically to the caudate and putamen, is a subcortical
structure that receives afferent inputs from a number of
different brain regions including association and sensorimotor cortices as well as the thalamus, and is considered
the primary input structure for the basal ganglia. Thus,
the striatum can be viewed as an assimilation zone for
information related to central nervous system functions
as broad as sensorimotor integration and motor function, motivation and reinforcement, and some aspects of
cognitive function such as working memory and executive function.77,78
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FIGURE 4. Serotonergic influence on a theoretical striatal microcircuit. The effects of serotonin on the behavior of striatal medium spiny neurons (MSNs) are
mediated by a number of different factors. Serotonergic afferents from the raphe have a mostly excitatory direct influence on MSNs that are mediated through
5-HT2A/2C, 5-HT4, and 5-HT6 receptors, although 5-HT5 receptors have an inhibitory influence on these cells. 5-HT1B receptors are prominently expressed in the
striatum, but are thought to exist primarily as presynaptic autoreceptors in this region (A). Similarly, serotonin has an excitatory direct effect on parvalbuminimmuoreactive (PV-IR) interneurons, which are at least mediated by 5-HT2C receptors (B). The excitatory effect of 5-HT observed in choline-acetyltransferase
immunoreactive interneurons ChAT-IR cells is mediated by a combination of 5-HT2C, 5-HT6, and 5-HT7 receptors (C). MSN behavior is also modulated by the
behavior of PV-IR and ChAT-IR cells. PV-IR cells have a powerful inhibitory effect on MSN firing that is mediated by GABAergic neurotransmission localized at
the MSN soma or dendrites. ChAT-IR cells have a relatively complex mix of excitatory and inhibitory effects on the behavior of PV-IR cells and MSNs. Cholinergic
transmission from ChAT-IR cells has a short-term activating effect on PV-IR cells that are mediated by nicotinic acetylcholinergic receptors (D), but can reduce
GABA release from PV-IR cells via presynaptic M2 receptors (E). ChAT-IR cells can also excite MSNs via M1 receptors (E), and can reduce release from
glutamatergic afferent terminals via M2 receptors (F).

From a structural perspective, the striatum has a
number of important differences compared to the PFC.
First, the laminar structure observed in the PFC is absent
in the striatum. Additionally, while the PFC has a mix of
inhibitory interneurons and excitatory cells that are
native to the region, the vast majority of striatal neurons
are GABAergic and thus inhibitory in nature. In fact,
there are at least four separate types of GABAergic cells
in the striatum. These include the medium spiny neuron
(MSN), which is this region’s principle projection cell, as
well as at least three chemically differentiated types of
striatal GABAergic interneuron.79 In addition, a fifth
type of striatal interneuron is cholinergic, rather than
GABAergic.79 The section below will focus on describing
medium spiny neurons, PV-IR fast-spiking interneurons,
and cholinergic interneurons and their relationships to
one another. These relationships, as well as the influence
of 5-HT on their behavior, are depicted in Figure 4.

Important striatal cell types
PV-IR fast-spiking interneurons

One of the most important classes of striatal GABAergic
interneuron is identified immunohistochemically by the

expression of the calcium binding protein parvalbumin
(PV). As in the frontal cortex, PV-IR interneurons are
characterized electrophysiologically by their fast firing rate
and short-duration action potential. Therefore we will refer
to these cell types interchangeably as striatal PV-IR
interneurons or as striatal fast-spiking interneurons.
PV-IR interneurons are believed to make up between 3%
and 5% of striatal neurons (for an excellent review, see
Kawaguchi et al79). These interneurons are thought to
receive a strong excitatory input from the neocortex, as well
as an inhibitory input from other striatal PV-IR cells.79,80 In
addition to these inputs, PV-IR cells are reported to form
electrical networks with one another via gap junctions,79
which may allow for the formation of neural assemblies with
other striatal fast-spiking interneurons.
The axons of striatal PV-IR cells have a basket-like
arborization pattern,79 with synapses directed at both the
dendritic tree and the soma of MSNs.80 Studies on the
synaptic connections between this class of interneurons
and MSNs have suggested that each MSN receives
connections from multiple PV-IR cells.80 Thus, given the
ideas that multiple PV-IR interneurons form inhibitory
synapses on the soma of each MSN cell, and further that
these cells may easily form inhibitory neural ensembles, it
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can be expected that PV-IR interneurons will have a
powerful inhibitory effect on the output of striatal
MSNs. Moreover, this idea is consistent with electrophysiological studies that have suggested that the majority
of inhibitory processes in the striatum are mediated by
PV-IR cells.81
Although there are at least 2 other types of GABAergic
interneurons that have been chemically or morphologically identified in the striatum,79 there is relatively little
accumulated knowledge on the calretinin-IR and nitric
oxide/neuropeptide Y/somatostatin-IR interneurons in
the striatum, particularly in terms of their relationship to
serotonergic neurotransmission. Therefore, this review
will not consider these cell types further.
Cholinergic interneurons

Striatal non-GABAergic interneurons are differentiated
from other striatal interneurons by a number of
morphological, histochemical, and electrical properties,
including a large soma with broadly branching dendritic
and axonal arbors; the expression of the acetylcholineproducing enzyme choline acetyltransferase (ChAT); and
a tonic, irregular firing pattern with low activation
thresholds.79 These cells receive excitatory inputs from
the cortex and thalamus, although the thalamic inputs
are thought to predominate in this cellular population.79,82 Throughout this article, we will refer to this
cellular population as ChAT-IR interneurons.
ChAT-IR interneurons modulate the behavior of other
striatal neuronal populations in a complex manner,
having a mix of excitatory and inhibitory effects on both
MSN and PV-IR cell populations. These influences have
been reviewed in detail in Goldberg and Reynolds,82 but
for the purpose of understanding how serotonergic
neurotransmission affects neuronal activity in the striatum, we will briefly discuss these effects here (summarized in Figure 4). ChAT-IR neurons have a fast excitatory
influence on PV-IR cells that is mediated by nicotinic
acetycholinergic receptors expressed on the soma.83
However, this excitatory effect is balanced by a slower,
inhibitory influence on GABA release that is mediated by
muscarinic M2 receptors expressed on striatal GABA
terminals.82 Additionally, Goldberg and Reynolds82
suggest that M2 receptors can have a similar effect on
the release of glutamate from cortical or thalamic
afferent terminals and that striatal ChAT-IR neurons
can have a direct stimulatory effect on MSN firing that is
mediated via muscarinic M1 receptors.
Medium spiny neurons

Whereas principle output cells in the cortex are
excitatory glutamatergic pyramidal neurons, principle
cells in the striatum are GABAergic in nature, and thus
efferents originating from the striatum have an

inhibitory effect on their projection regions. These
striatal principle cells are MSNs, which are thought to
represent between 80% and 98% of the neurons present
in the neostriatum (for a review, see Tepper et al84).
From a morphological perspective, MSNs are characterized by their medium size and spiny dendritic arbors.85
MSNs can be further subdivided into at least 2 separate
but equally represented populations based on neuropeptide and neurotransmitter receptor expression: those
expressing enkephalin and dopamine (DA) D2 receptors,
and those expressing dynorphin, substance P, and DA D1
receptors.86–89 MSNs receive excitatory glutamatergic
afferents from the neocortex and thalamus,80 as well as
serotonergic afferents from the midbrain raphe nuclei.
However, the MSN subpopulations noted above preferentially send efferent projections to separate portions of
the basal ganglia. MSNs expressing enkephalin and DA
D2 receptors project preferentially to the globus pallidus,
while those expressing dynorphin, substance P, and DA
D1 receptors send efferents to the substantia nigra.87,88
In addition to MSN axon efferents sent to basal ganglia
targets, MSN neurons also send axon collaterals to other
MSN cells in the striatum that synapse in the dendritic
arbor.79 This phenomenon, in combination with the
inhibitory nature of these cells, originally led to a
hypothesis that striatal MSNs form a competitive lateral
inhibitory network, where activation of one MSN leads to
inhibition of surrounding MSNs. However, more recently
this theory has been modified in light of electrophysiological evidence demonstrating that the inhibitory effect
of a given MSN on the firing of surrounding MSNs is very
weak, owing probably to the dendritic insertion of MSNMSN axon collaterals.80,81 A modified theory suggests
that lateral inhibition may still be possible in MSN
networks, based on the fact that each MSN sends axon
collaterals to about 1 in 6 of its surrounding MSNs and
receives inputs from approximately 450 other local
MSNs. In this theory, MSNs that are not connected to
one another via axon collaterals but receive similar
excitatory inputs may form neural assemblies that can
inhibit surrounding MSNs in the aggregate (reviewed in
Wilson80). Thus, it is possible that MSNs have a relatively
weak lateral inhibitory influence on other MSNs in the
striatum, but this is currently considered to represent a
small minority of the total phasic inhibitory drive on
striatal MSN activity.80
In the following section we will review evidence on the
regional and cellular pattern of 5-HT receptor expression for each of the above-mentioned striatal cell types.

Serotonergic receptor expression within the striatum
5-HT1 receptors

5-HT1A receptor binding in the caudate and putamen
it is extremely low29,90 (Figure 2, panels A and B).
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Thus, although there may be some very weak expression of
5-HT1A receptors within the striatum of the rodent brain,91
we will consider it to be essentially absent in this region.
In contrast, studies of 5-HT1B receptor expression in
the striatum showed moderate to strong expression
levels of mRNA92 as well as protein33,35 (Figure 2, panels
C and D), which may indicate that 5-HT1B receptors are
postsynaptically expressed in the striatum or are
expressed on interneurons. A mouse study by Ghavami
et al,91 using a conditional 5-HT1B receptor knockout
approach, demonstrated that 5-HT1B receptors made by
striatal MSNs are primarily sent to the basal ganglia
projection regions. These data might suggest that striatal
5-HT1B receptors are localized primarily on terminals
originating from the midbrain raphe.92,93 However, duallabeling immunohistochemistry has provided evidence
demonstrating that 5-HT1B receptors are also present on
striatal PV-IR and ChAT-IR interneurons.38 It is not
known whether there is a somatodendritic expression of
5-HT1B receptors in these cell types, and it is possible
that 5-HT1B receptors act as terminal heteroreceptors in
striatal PV-IR and ChAT-IR interneurons.
5-HT1D receptors are closely related to 5-HT1B receptors in the brain and often have a similar, although much
more rarified, expression pattern. However, Bruinvels
et al33 demonstrated that, in the striatum, 5-HT1D
receptor specific binding constituted about 11% of the
total binding of a radioligand that is nonselective for
5-HT1B/1D receptors. However, given evidence that
5-HT1D receptors form a heterodimer with 5-HT1B
receptors when they are co-expressed,94 it can be
questioned whether these receptors should be considered
separately.
Based on these data, striatal 5-HT1B receptors may act
primarily to modulate extracellular concentrations of
5-HT by acting as an inhibitory autoreceptor at serotonergic terminals. Moreover, this idea is supported by
data from microdialysis experiments.36
If 5-HT1B receptors are present in the somatodendritic region of PV-IR and ChAT-IR interneurons, then
stimulation of these receptors should drive down the
activation state of these interneurons. Alternatively,
5-HT1B receptors expressed as terminal heteroreceptors
in these cells may act to reduce release of GABA or
acetylcholine, respectively, without markedly modulating cellular excitability at the soma. Which of these
subcellular expression patterns is present in striatal
interneurons is essentially unknown at this time.
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caudal portions of the striatum.95 Cornea-Hebert et al41
have confirmed 5-HT2A receptor immunoreactivity in
the majority of striatal MSNs. Furthermore, Ward and
Dorsa95 found that 5-HT2A receptor mRNA is present in
MSNs that project to both the globus pallidus and
substantia nigra. Cornea-Hebert et al41 also observed
some 5-HT2A receptor immunoreactivity in a population
of neurons characterized by a large soma. These cells are
presumably cholinergic interneurons based on the
large soma.
5-HT2C receptors are present in the striatum at
moderate levels44 and are expressed in striatal MSN
cells,95,96 and once again do not appear to discriminate
between MSN cells projecting to the globus pallidus vs
the substantia nigra.95 Although we have not been able to
identify any systematic immunohistochemical studies
that have examined whether 5-HT2C receptors are
present in striatal interneuron populations, electrophysiological experiments would suggest 5-HT2C receptor
expression on striatal fast spiking interneurons97 and
ChAT-IR cells.98
Within the frontal cortex, 5-HT2A receptors have
mixed effects on the behavior of the microcircuitry by
activating pyramidal neurons and GABAergic interneurons. Within the striatum, a similar picture of the effects
of 5-HT2A/2C receptor stimulation emerges, with activation of these receptors likely to stimulate the striatal
MSN projection cells as well as PV-IR and ChAT-IR
interneurons.
5-HT3 receptors

5-HT3 receptor expression in the striatum is extremely
low46 (Figure 2, panels E and F). There are reports of a
few strongly 5-HT3 receptor-IR cells present within the
striatum48; however, the identity of these cells is
not known.
5-HT4 receptors

5-HT4 receptor expression is moderate to high in the
striatum with an increasing rostro-caudal gradient.51,99
Given that the regional profile of 5-HT4 receptor mRNA is
very similar to that seen using autoradiography within the
striatum,51,99 it can be hypothesized that 5-HT4 receptors
primarily have a somatodendritic expression pattern.
Egeland et al38 found that striatal PV-IR and ChAT-IR
interneurons do not express 5-HT4 receptors. Given the
prominence of 5-HT4 receptors in the striatum, it is
therefore likely that MSN cells express 5-HT4 receptors;
however, this awaits a definitive confirmation.

5-HT2A/2C receptors

5-HT2A receptors are only moderately expressed in the
striatum,41 although it should be noted that at least one
research group has noted a gradient in 5-HT2A receptor
mRNA expression, with more dense expression in the

5-HT5 receptors

Striatal 5-HT5 receptor immunoreactivity is weak, and
there is a paucity of evidence on the cell types expressing
5-HT5 receptors. The little that is available suggests that
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these receptors are expressed by MSNs but not cholinergic cells.53 Thus, 5-HT5 receptor activation might have
an inhibitory effect on striatal MSN activity, and in fact
this is one of the few serotonergic inhibitory receptors
that have been found in the striatum. It remains to be
seen whether 5-HT5 receptors are present in any of the
GABAergic interneurons of the striatum.
5-HT6 receptors

5-HT6 receptors are densely expressed in the striatum,
where they are primarily associated with a postsynaptic,
dendritic expression pattern.55 5-HT6 receptors have
been observed in striatal MSN cells95,100 in a manner
that does not differentiate between MSNs projecting to
the globus pallidus or the substantia nigra,95 continuing
with the apparent theme that serotonergic receptors do
not discriminate between these alternate projections to
the basal ganglia. In human striatal tissue, Marazziti
et al101 found that 5-HT6 receptors were present in
putatively PV-IR cells. However, in rodent tissue,
another group found no evidence of 5-HT6 receptor
mRNA in PV-IR cells.100 Electrophysiological data have
suggested the presence of 5-HT6 receptors in striatal
cholinergic (ChAT-IR) interneurons.98 Thus, stimulation of striatal 5-HT6 receptors can be expected to
activate striatal MSN and ChAT-IR interneurons,
whereas it is unclear that these receptors are present in
striatal PV-IR interneurons.
5-HT7 receptors

Within the striatum, Neumaier et al57 reported moderate
levels of 5-HT7 receptor-like immunoreactivity, and
5-HT7 receptor-selective autoradiographic binding is
present at relatively low levels in the rodent (see
Figure 2, panels G and H) and human striatum.102 We
have not been able to identify any anatomical studies that
characterize the striatal cellular subtypes expressing
5-HT7 receptors. However, Bonsi et al98 found that
cholinergic interneurons expressed 5-HT7 receptor
mRNA, and further that the activating effect of 5-HT
on striatal cholinergic cells could be attenuated by
application of the 5-HT7 receptor selective antagonist
SB269970. Thus, 5-HT7 receptors are likely to be
expressed at the least in striatal ChAT-IR interneurons,
where they have a stimulatory effect.

Serotonergic modulation of striatal neuronal subtypes and
overall striatal output
PV-IR fast-spiking interneurons

In striatal PV-IR fast-spiking interneurons, there is
evidence supporting the presence of excitatory 5-HT2C
receptors as well as inhibitory 5-HT1B receptors. It is not
known whether the 5-HT1B receptor immunoreactivity is

associated with a somatodendritic expression, as has
been observed in the hippocampus,39,40 or if it is
expressed primarily as a terminal heteroreceptor. Additionally, it is unknown whether 5-HT1B and 5-HT2C
receptors constitute the entire complement of serotonergic receptors expressed by striatal PV-IR interneurons. Furthermore, it is somewhat difficult to gauge the
relative level of affinity at these targets, as the range of
observed affinities for 5-HT at these 2 receptors overlaps
(Table 1). Based on these uncertainties, it is unclear how
physiological levels of 5-HT will alter the behavior of
striatal PV-IR interneurons, although one might expect
to find mixed effects of 5-HT stimulation. However, it
should be noted that electrophysiological investigations
into the effects of 5-HT stimulation on PV-IR interneuron activity have not found any 5-HT1B receptor
mediated inhibitory currents in striatal PV-IR interneurons (see discussion below), which may either suggest this
receptor is expressed as a terminal heteroreceptor, or
may call its presence in these cells into question
altogether. Taken together, these data may suggest that
striatal PV-IR interneurons will be primarily excited by
5-HT, via a 5-HT2C receptor mediated mechanism.
Cholinergic interneurons

There is evidence supporting the presence of excitatory
5-HT2C, 5-HT6, 5-HT7, and inhibitory 5-HT1B receptors
in striatal ChAT-IR interneurons. This cellular profile
may suggest that 5-HT will bias striatal ChAT-IR
interneurons toward excitation.
Medium spiny neurons

In striatal MSNs, the available evidence primarily
supports the presence of excitatory 5-HT receptors,
including 5-HT2A, 5-HT2C, 5-HT4, and 5-HT6 receptors,
although inhibitory 5-HT5 receptors are also present.
Given that 5-HT5 receptors are expressed in a relatively
weak manner in the striatum, and have a relatively low
affinity for 5-HT by comparison to at least 5-HT2A,
5-HT4, and 5-HT6 receptors (Table 1), it is likely that
5-HT will have primarily excitatory direct effects on MSN
firing behavior.

Electrophysiological effects of 5-HT in the striatum
In vivo electrophysiology

Although the available evidence suggests that primarily
excitatory serotonergic receptor targets are expressed on
the major cell types in the striatal circuitry, studies of the
effects of 5-HT on neuronal firing have overwhelmingly
shown an inhibitory effect. For example, Rebec and
Curtis103 found in paralyzed (not anesthetized) rodents
that 5-HT application by microinjection at a 10 µM
concentration suppressed firing at neurons close to the
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microinjection cannula. Similar results were found in
other studies that investigated this issue,104–106 although
in some neurons a brief excitation was followed by
inhibition.104 It should be noted that in at least one case,
more units were excited than inhibited.107 The identities
of the recorded units in these in vivo experiments were
not further characterized, but, given the ascendant
proportion of cells that MSNs represent within the
striatum, it is most likely that the recorded neurons
are primarily MSNs. Interestingly, although excitatory
5-HT2A receptors are present on MSNs, and further that
5-HT2C receptors are present on all 3 major striatal
neuronal types discussed here, 5-HT2A/2C receptor
agonists mimicked the overwhelmingly inhibitory effects
of 5-HT application. We were not able to identify any
in vivo electrophysiology studies that examined the
effects of 5-HT on identified fast-spiking interneurons
or cholinergic interneurons within the striatum.

In vitro electrophysiology

In the one in vitro study we identified that attempted to
examine the response of MSNs to 5-HT in acutely
dissociated cells, the authors found that the majority of
cells were excited by the bath application of 5-HT at 10–
60 µM concentrations. This result stands in stark
contrast to the behavior of putative MSNs recorded
in vivo using anesthetized and paralyzed rats, but is in
line with the primarily excitatory complement of
5-HT receptors that has been found on striatal MSNs.
Given that the in vivo experiments reported above
used similarly high 5-HT concentrations, the most
probable explanation for this difference lies in the fact
that the recorded MSNs were acutely dissociated from
the striatal network, which divorces the subject cell from
the inhibitory cells that would normally govern its
behavior.
Blomeley and Bracci97 used a slice electrophysiology
preparation to demonstrate that high concentrations
of 5-HT (30 µM) strongly increased the excitability of
striatal fast-spiking interneurons. These authors
further demonstrated that this excitatory response was
blocked by a 5-HT2C receptor antagonist. Moreover, this
research group did not report the presence of any 5-HT
mediated inhibitory currents in these cells that could be
attributed to 5-HT1B receptors, which would seem to be
at odds with the somatic 5-HT1B receptor expression
observed in striatal PV-IR interneurons by Egeland
et al.38
In vitro electrophysiological evidence from at least 2
research labs also supports the idea that high concentrations of 5-HT have an excitatory effect on striatal
cholinergic interneurons. Blomeley and Bracci108 found
that 30 µM 5-HT excited striatal cholinergic cells and
further that the 5-HT2 receptor antagonist ketanserin

17

antagonized this effect. Similarly, Bonsi et al98 found that
50 µM 5-HT excited striatal cholinergic interneurons,
that the 5-HT2A/2C receptor agonist DOI mimicked this
effect, and finally that a 5-HT2C receptor antagonist
reversed this excitation. This group also showed that the
excitatory effect of 5-HT could be reduced by 5-HT6 and
5-HT7 receptor selective antagonists.

Hypothesized effects of 5-HT, SSRIs, and vortioxetine on the
overall striatal circuit
5-HT and SSRIs

The electrophysiological data on the effects of 5-HT on
striatal PV-IR and ChAT-IR firing suggest that 5-HT has
an excitatory effect on these cell types. Additionally, the
profile of 5-HT receptor expression on striatal MSN cells
also suggests that 5-HT should have primarily excitatory
direct effects. This is supported by data showing that
5-HT activates MSN cell firing when these cells are
dissociated from the striatal network, but it is firmly at
odds with the electrophysiological effects of 5-HT on
putative MSN cells recorded in vivo.
The most plausible explanation for this apparently
paradoxical effect of 5-HT on striatal MSN activity is that
the concomitant activation of striatal PV-IR interneurons has a downstream inhibitory action on MSNs that
overwhelms 5-HT’s direct excitatory effects on these
cells. This reasoning is based on the fact that striatal
PV-IR interneurons have inhibitory axo-somatic insertions on numerous MSN cells, which will tend to
powerfully and negatively modulate MSN activity.
Furthermore, each MSN cell receives inhibitory inputs
from multiple PV-IR interneurons. This phenomenon,
along with the presence of electrical gap junctions
between striatal PV-IR cells, will tend to multiply the
inhibitory influence of PV-IR interneurons on MSN
behavior. It is possible that some of 5-HT’s effects on
MSN firing are also mediated via striatal ChAT-IR
interneurons. However, ChAT-IR interneuron activation
is expected to have a mixture of excitatory and inhibitory
effects that seem unlikely to clearly bias MSN output in
either direction. Therefore, the strong inhibitory effect
of 5-HT on MSN firing is most likely mediated primarily
through PV-IR interneuron activation.
Based on this line of reasoning, we hypothesize that
SSRIs will have primarily inhibitory local effects on
striatal MSN firing under acute conditions. Given that
5-HT2C receptors are the only excitatory serotonergic
targets identified on striatal PV-IR interneurons, the
degree to which this local inhibitory effect of SSRIs is
maintained after chronic administration might be dictated by the degree to which 5-HT2C receptors desensitize or downregulate in response to long-term
stimulation. Thus, it is possible that the local inhibitory
effect of SSRIs on MSN firing will be decreased after
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chronic administration. Additionally, given that SSRIs
tend to reduce cortical pyramidal neuron firing after
chronic administration, striatal PV-IR cells may also
receive an attenuated excitatory drive from the cortex
after chronic SSRI treatment. Thus, it seems plausible to
hypothesize that long-term SSRI treatment will attenuate
the reduction in MSN firing. However, we were unable to
identify in vivo or in vitro electrophysiological studies of
the effects of acute or long-term SSRI administration on
striatal neuron firing.

Vortioxetine

Although vortioxetine has markedly different effects by
comparison to SSRIs within the frontal cortex, this may
not be the case within the striatum. 5-HT3 and 5-HT1A
receptors are largely absent in the striatum, and thus
cannot be expected to modulate the effects of this
network locally. 5-HT7 receptors, where vortioxetine
acts as an antagonist, have been confirmed in striatal
ChAT-IR interneurons, and thus vortioxetine may
remove some of the excitatory influence of 5-HT on this
cell population. But it is seems unlikely that altered
activation of striatal ChAT-IR interneurons will clearly
bias MSN output in either direction. 5-HT1B receptors,
where vortioxetine functions as a partial agonist
in vivo,76 are thought to primarily exist in the striatum
as terminal autoreceptors. Thus vortioxetine’s primary
5-HT1B receptor mediated effect in this region will
probably be an enhancement of extracellular 5-HT by
comparison to an SSRI. However, the question of
whether vortioxetine drives greater extracellular 5-HT
concentrations in the striatum than an SSRI is currently
untested. Additionally, if 5-HT1B receptors are expressed
in a meaningful way on striatal PV-IR interneurons, then
vortioxetine’s 5-HT1B receptor partial agonism may have
the effect of attenuating the only inhibitory influence
5-HT would be expected to have on PV-IR interneurons,
thereby increasing their excitability and further driving
down the activity of MSNs.
Therefore, when considering local effects of vortioxetine within the striatum only, the emerging theme is
that vortioxetine will increase striatal PV-IR interneuron
activation and reduce the output of striatal MSN
projection neurons downstream. Moreover, these inhibitory effects on striatal MSN behavior will be qualitatively
similar to those expected from SSRIs. However, the
question of how vortioxetine may modulate striatal
neuron activity is complicated by the fact that striatal
MSN and PV-IR interneurons receive excitatory inputs
from the cortex,80 where vortioxetine increases activity
in projection neurons.18 Thus, vortioxetine may have
both local and non-local effects that will tend to activate
striatal PV-IR interneurons, while in MSN cells, vortioxetine’s local GABA-mediated inhibitory effects and

nonlocal excitatory effects may be at odds with one
another. These contradictory actions may suggest that
vortioxetine will produce a mix of excitatory and
inhibitory effects on MSN activity, but we hypothesize
that these effects will skew toward inhibition of MSN
firing.

Conclusions
The recurrent theme underlying this article is that 5-HT
modulates GABA and glutamate neurotransmission
differently from brain region to brain region, based
simply on the circumscribed expression pattern exhibited by each serotonergic target. Using a more complex
analysis of receptor expression and electrophysiological
data, we have generated several hypotheses about how
5-HT in general and vortioxetine in particular will
modulate the behavior of GABAergic and glutamatergic
cells in the PFC and striatum.
Within the PFC, we have hypothesized that acute
SSRI administration will have mixed excitatory and
inhibitory effects on GABAergic interneurons and
principle pyramidal neuron firing that will not clearly
bias the output of the overall network strongly in either
direction. However, chronic SSRI administration may
lead to a reduction in glutamatergic pyramidal neuron
firing. Within the striatum, SSRIs will acutely reduce the
activity of MSNs by enhancing the activity of GABAergic
fast-spiking interneurons, and this effect may be attenuated by chronic administration. Recent computational
modeling studies have suggested that increased activity
in fast-spiking interneurons and the resulting reduction
in MSN activity may contribute to reduced impulsive
behavior.109 Although, to our knowledge, this idea has
not yet been empirically evaluated, it is consistent with
preclinical studies showing that SSRIs reduce some
aspects of impulsivity.110,111
By contrast, vortioxetine is hypothesized to reduce
PFC GABAergic inhibitory tone through a variety of
serotonergic mechanisms, including 5-HT3 receptor
antagonism, leading to an increase in the activity of
excitatory glutamatergic pyramidal projection neurons.
This notion is supported by electrophysiological recordings showing that vortioxetine has strong excitatory
effects on putative pyramidal neurons.18 This increase in
cortical glutamate neurotransmission is thought to be
responsible in part for vortioxetine’s beneficial effects on
some aspects of cognitive function.16 Locally within the
striatum, vortioxetine is hypothesized to have qualitatively similar effects as SSRIs, ie, enhancing the activity
of striatal GABAergic PV-IR interneurons, leading to an
overall reduction in the activation of striatal MSNs. But
vortioxetine’s effects on striatal MSN function may also
be due in part to effects driven by the enhancement of
frontal cortex pyramidal neurons, which are thought to
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make excitatory connections with striatal PV-IR and
MSN cells. Thus, the combination of local and nonlocal
effects of vortioxetine may ultimately lead to mixed
excitatory and inhibitory effects on striatal MSN output,
although in our view, vortioxetine is most likely to bias
MSN function toward inhibition. This hypothesis clearly
needs to be confirmed by empirical data.
Future research should evaluate these hypotheses in
further detail by examining the effects of vortioxetine on
cortical and striatal signaling pathways. Additionally, if
technically feasible, then future studies should investigate vortioxetine’s effects on GABA and glutamate
neurotransmission (eg, pyramidal neuron firing) in
awake animals during the conduct of a cognitive task.
Ideally, it will be important to include translational
demonstrations of these effects of vortioxetine in
humans. However the technical feasibility of such a
demonstration is uncertain, given current limitations in
non-invasively measuring GABA and glutamate
neurotransmission.

Limitations
There are a number of important limitations to consider
when evaluating this body of work. First and foremost,
there is a relative paucity of cell-type specific 5-HT
receptor expression or electrophysiological data
available for the striatum, which implies uncertainty
around hypotheses generated for the effects of 5-HT,
SSRIs, and vortioxetine. Additionally, we do not
currently have electrophysiological data on vortioxetine’s effects in the striatum with which to check the
validity of these hypotheses. Furthermore, the available
electrophysiological data on how 5-HT modulates striatal neurotransmission are generally characterized by the
use of high concentrations, which may not be physiologically relevant. It is important to note that the
hypotheses of the effects of 5-HT, SSRIs, and vortioxetine are primarily developed using anatomical and
electrophysiological data from rodents. The biology that
drives serotonergic modulation of GABA and glutamate
neurotransmission may not translate across species into
humans. Additionally, vortioxetine’s affinities for some
of its receptor targets, most notably 5-HT1A and 5-HT7
receptors, are approximately 10-fold weaker at the
rodent versions than they are at their human counterparts.113 Therefore, the degree to which these concepts
of serotonergic modulation of GABA and glutamate
neurotransmission will translate into humans is
unknown at this time.
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